This comparison between single-dose tafenoquine after semi-quantitative G6PD screening and 7-day primaquine (with or without G6PD screening) indicates that tafenoquine is a cost-effective option for improving health outcomes for the population at risk of malaria in Brazil. This evidence concerns the gene G6PD and malaria.